Implante de Port-o-Cath para quimioterapia antineoplásica em um canino: relato de caso / Implant of Port-o-Cath for antineoplastic chemotherapy in a canine: case report

O Port-o-Cath é um cateter venoso central totalmente implantável, o qual permite a infusão de quimioterápicos, hemoderivados, nutrição parenteral e coleta de sangue. Este trabalho relata o caso de um canino com um tumor no membro pélvico que foi tratado cirurgicamente e recebeu o cateter para a quimioterapia antineoplásica. A paciente possuía um sarcoma sinovial, tumor incomum em cães, que acomete normalmente as articulações e exige terapia multimodal. O tratamento foi feito em duas etapas; na primeira, o membro foi amputado e, na segunda, foi realizado o implante do Port-o-Cath e exérese de nódulo metastático. A cadela respondeu satisfatoriamente à cirurgia e realizou as sessões de quimioterapia com perfeito funcionamento do cateter, indo a óbito por outras causas 90 dias após o procedimento. O implante de Port-o-Cath para a quimioterapia é um grande aliado à terapia multimodal preconizada para o câncer, podendo o cateter ser considerado em pacientes que necessitem de medicação quimioterápica por longo período.(AU)

The Port-a-Cath is a totally implantable central venous catheter that allows the infusion of chemotherapeutic agents, blood products, parenteral nutrition, and blood sample collection. This work reports the case of a dog with a tumor in the pelvic limb that was treated surgically and received the catheter for cancer chemotherapy. The patient was diagnosed with synovial sarcoma, an uncommon tumor in dogs that usually affects the joints and requires multimodal therapy. The treatment was done in two steps, in the first the limb was amputated and in the second the Port-a-Cath implantation and the excision of the metastatic nodule were performed. The dog responded well to surgery and chemotherapy sessions held with proper functioning of the catheter, and died from other causes 90 days after the procedure. The implantation of Port-a-Cath for chemotherapy is a great ally of multimodal therapy recommended for cancer, so this catheter may be considered for patients requiring chemotherapy medication for a long period.(AU)

Función pulmonar en adultos jóvenes con síndrome de Down: estudio transversal / Pulmonary function in young adults with Down syndrome: a cross-sectional study

OBJETIVO: Comparar la función pulmonar entre adultos con síndrome de Down (SD) y adultos sanos. MÉTODO: Participan en el estudio 34 adultos jóvenes (17 con SD y 17 controles sanos) con edades comprendidas entre los 20 y 40 años. Se registran en ambos grupos variables antropométricas y de función pulmonar: volumen espiratorio forzado en un segundo (FEV1), capacidad vital forzada (FVC), flujo espiratorio máximo (PEF) y la relación FEV1/FVC. RESULTADOS: El grupo con SD presentó un mayor peso e índice de masa corporal (IMC) que el grupo control (31,4 ± 4,6 vs.23,4 ± 1,3 kg/m2, p < 0,001). Se registraron valores significativamente menores en la función pulmonar de los sujetos con SD que en la del grupo control: PEF (238,4 ± 89,4 vs.387,4 ± 52,9 l/min, p ≤ 0,001), FVC (2,2 ± 0,7 vs.3,1 ± 0,4 l, p ≤ 0,001) y FEV1 (1,9 ± 0,6 vs.3,1 ± 0,5 l, p ≤ 0,001). No se observaron diferencias entre grupos en el FEV1/FVC. Se observó una correlación inversa entre el IMC y el PEF (r = -0,691, p < 0,001), la FVC (r = -0,555, p = 0,001) y la FEV1 (r = -0,617, p < 0,001). CONCLUSIÓN: Los adultos con SD muestran una reducción de la función pulmonar cuando se les compara con controles de su misma edad. La función pulmonar correlaciona inversamente con el IMC

AIM: To compare the pulmonary function of young adults with Down syndrome (DS) with healthy subjects. METHODS: Thirty-four young adults (17 with DS and 17 apparently healthy controls), aged 20-40, participated in this study. Anthropometric variables and lung function, namely forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), and the fraction of FVC expired in one second (FEV1/FVC%), were assessed in both groups. RESULTS: The group of young adults with DS had a lower height and higher body mass index (31.4 ± 4.6 vs.23.4 ± 1.3 kg/m2, p < 0.001). As regards pulmonary function, the group of participants with DS showed significantly lower values for PEF (238.4 ± 89.4 vs.387.4 ± 52.9 L/min, p ≤ 0.001), FVC (2.2 ± 0.7 vs.3.1 ± 0.4 L, p ≤ 0.001) and FEV1 (1.9 ± 0.6 vs.3.1 ± 0.5 L, p ≤ 0.001), when compared to subjects of the CONTROL GROUP: No changes were observed in FEV1/FVC%. An inverse correlation was observed between the body mass index and the PEF (r = −0.691, p < 0.001), the FVC (r = −0.555, p = 0.001), and the FEV1 (r = −0.617, p < 0.001). CONCLUSIONS: Young adults with DS showed reduced pulmonary function in comparison to age-matched controls. Additionally, the pulmonary function was inversely correlated with body mass index

Revisión del tratamiento farmacológico en la menopausia / Review of pharmacological treatment of the menopause

No disponible

No disponible